Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma

BACKGROUND: Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is a novel anticancer drug used for treating several types of cancers. In this study, we aimed to determine the role of ibrutinib on GBM. METHODS: Ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jin, Liu, Xiaoyang, Hong, Yongzhi, Wang, Songtao, Chen, Pin, Gu, Aihua, Guo, Xiaoyuan, Zhao, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513110/
https://www.ncbi.nlm.nih.gov/pubmed/28716053
http://dx.doi.org/10.1186/s13046-017-0549-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513110/
https://www.ncbi.nlm.nih.gov/pubmed/28716053
http://dx.doi.org/10.1186/s13046-017-0549-6

Ejemplares similares